Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
語言
全文檢索
題名
作者
主題
索引號
ISBN/ISSN
標簽
檢索
高級檢索
Inability to Tolerate Standard...
引用
發送短信
推薦此
打印
導出紀錄
導出到 RefWorks
導出到 EndNoteWeb
導出到 EndNote
Permanent link
導出完成 —
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
Show other versions (2)
書目詳細資料
Main Authors:
Sive, J
,
Buck, G
,
Fielding, A
,
Lazarus, H
,
Litzow, MR
,
Luger, S
,
Marks, D
,
McMillan, A
,
Richards, S
,
Rowe, J
,
Tallman, MS
,
Goldstone, A
格式:
Conference item
出版:
2010
持有資料
實物特徵
Other Versions (2)
相似書籍
職員瀏覽
相似書籍
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
由: Sive, J, et al.
出版: (2010)
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
由: Sive, J, et al.
出版: (2010)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
由: Sive, J, et al.
出版: (2012)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
由: Fielding, A, et al.
出版: (2007)
Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
由: Fielding, A, et al.
出版: (2010)